Diabetes-Check

Diabetes screening panel combining fasting glucose with HbA1c (glycated haemoglobin). Fasting glucose provides a snapshot of current glycaemic status, while HbA1c reflects average blood glucose control over the preceding 8-12 weeks. Together they detect diabetes and pre-diabetes with higher sensitivity than either marker alone. EUR 27.69 under GOAe 1.0x rates.

This two-marker diabetes panel provides complementary perspectives on glucose metabolism. Fasting glucose is a point-in-time measurement: a level of 7.0 mmol/L (126 mg/dL) or above on two separate occasions is diagnostic of diabetes mellitus, while 5.6-6.9 mmol/L (100-125 mg/dL) identifies impaired fasting glucose -- a pre-diabetic state. However, a single fasting glucose can be affected by acute stress, recent meals (if the patient did not fast adequately), medications, and inter-day biological variation. HbA1c eliminates these sources of variability by measuring the percentage of haemoglobin molecules that have undergone non-enzymatic glycation over the 120-day lifespan of red blood cells. An HbA1c of 6.5% (48 mmol/mol) or above is an independent diagnostic criterion for diabetes mellitus, accepted by both the WHO and the American Diabetes Association. Values between 5.7-6.4% (39-47 mmol/mol) identify pre-diabetes. The clinical power of combining both markers lies in their complementary sensitivity. Some patients have normal fasting glucose but elevated HbA1c (indicating post-prandial hyperglycaemia missed by the fasting sample), while others show the reverse pattern. Using both markers together catches approximately 30% more cases of pre-diabetes and early diabetes than either marker alone. Type 2 diabetes affects approximately 8-9% of the German adult population, with an estimated additional 2 million undiagnosed cases. The German Diabetes Risk Score (DIfE) identifies high-risk individuals based on age, waist circumference, hypertension, diet, and family history, but biochemical confirmation requires blood testing. Pre-diabetes is the most actionable finding: the Finnish Diabetes Prevention Study and the US Diabetes Prevention Program both demonstrated that lifestyle intervention (5-7% weight loss plus 150 minutes of weekly moderate exercise) reduces progression to type 2 diabetes by 58%. Early detection through screening panels like this one enables intervention at the stage where it is most effective. The GOAe 1.0x price is EUR 27.69 -- glucose at EUR 2.68 plus HbA1c at EUR 13.41 plus blood draw and outpatient fees. No physician referral is needed.